Replies to post #293428 on Avid Bioservices Inc (CDMO)

[4OurRetirement]

Thanks,I Agree. Only 5k VisibleInTheASK Above$.64 Until 41k@$.70...

And it appears PPHM may finally be starting its reversal on this third day of attacks on the PPS.

Low today hit $.6150 and already back to $.64

I'm thinking we should end green...

Glta StockHOLDERS!

Besides, it is always good to find another measurable way to show that treating with Bavi is better than treating without :-)

[cheynew]

Thanks for that, CP. Just wondering if you have any thoughts on Friday's trading and the strange flat lining. Unusual, even by PPHM standards.

[EndoTarget]

Slingshot effect.

Keep it really realy quiet then KabOOm!

The wording is especially for people with the knowledge. Those will gain...

[biopharm]

CP.. what do you think of "cold tumors" popping up with Heat Biologics / BMY?

"March 21 2017

....
.....
To-date, 5 patients have been enrolled in the low tumor infiltrating lymphocytes (TIL) cohort (patients with “cold” tumors). Three of these 5 patients (60%) have experienced significant tumor reduction, which is higher than the 10% response rate of low TIL patients reported for existing data on nivolumab alone.1"
...
...
http://www.heatbio.com/newsroom/press-releases/detail/555/heat-biologics-reports-positive-interim-phase-2-lung-cancer";

------

Now, HS-110 may be a PS Targeting drug....is this possibly why Rahul stopped poppinv up at PPHM cc and also why Jeff Hutchins left and lands over at Heat Biologics... ?

HS-110 (viagenpumatucel-L)

Advanced Non-Small Cell Lung Cancer (“NSCLC”)

HS-110 utilizes ImPACT-modified lung cancer cells to stimulate a patient’s immune system to activate a cytotoxic T cell response against a range of antigens that are known to be expressed by a high proportion of patients with NSCLC. The backbone cell line for HS-110 was selected based on antigenic overlap with patient tumor specimens, including known antigens as well as many additional known and unknown antigens. This approach provides a significant advantage over single antigen approaches by reducing the risk of antigen-loss variants emerging post-treatment and by addressing the underlying genetic and antigenic heterogeneity within tumors.

Heat Biologics is conducting two clinical trials evaluating HS-110 for the treatment of NSCLC:

A multi-arm Phase 2 trial using HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®). For more information reference study protocol NCT02439450 on clinicaltrials.gov.
A Phase 2 randomized, controlled trial using HS-110 in combination with cyclophosphamide. For more information reference study protocol NCT02117024 on clinicaltrials.gov.

http://www.heatbio.com/pipeline/hs-110

-------------------

....and Heat Biologics would require PS Targeting if they use "cyclophosphamide"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130082441

....which is why I think HS-110 may be PS Targeting

[sunstar]

BioBS2012, how do you read the company disclosers posted by CP and associated with:

Session PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress
CT159 / 25 - IFN-? analysis in blood and tissue as a potential prognostic and/or predictive biomarker

I read this as: these scientists have been working with/for all the companies listed behind their names. Why would a scientist need to disclose the companies that they have done work for, if it was in the past, or on other projects? I could see the necessity if they were contracted by these companies to support this particular project.

Disclosures

N. Kallinteris: ; Peregrine Pharmaceuticals Inc. L. Horn: ; Abbvie. ; BMS. ; Merck. ; Eli Lilly. ; Genentech. ; Xcovery. ; Boehringer Ingelheim. M. Tang: ; Peregrine Pharmaceuticals Inc. T. Guennel: ; Precision for Medicine. S. Yin: ; Peregrine Pharmaceuticals, Inc. J. Lai: ; Peregrine Pharmaceuticals, Inc. J. Shan: ; Peregrine Pharmaceuticals, Inc. R.E. Sanborn: ; AMGEN. ; Seattle Genetics. ; Peregrine Pharmaceuticals Inc.. ; Ariad. ; AstraZenecca. ; Research funding; Bristol-Myers Squibb. ; Research funding; MedImmune. ; Research funding; Merck.

IMO

sunstar